Septerna, Inc. SEPN
Updated: 18 Jun 2026
No signal published yet
We already track Septerna and collect the news. No signal is published yet — follow the company free and we will email you when that changes, or run a quick check now.
Email when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Temporary check — not Firelda's published signal.
General analysis — not personal advice.
Want to follow Septerna, Inc.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow Septerna free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Recent News
In May 2026, Septerna reported positive Phase 1 data for SEP-631 and initiated a Phase 1 trial for SEP-479, an oral treatment for hypoparathyroidism. The company also reported a cash position of $522.1 million, which is expected to support operations through 2029.
What Firelda Watch includes for Septerna, Inc.
Add the company to your watchlist and get all of this automatically.
- Free: 3 companies on your watchlist
- Change history and monitoring for every company you follow
- Sunday weekly brief — a short weekly roundup
- Watch/Ultra: same-day email when something material happens
Want to see what a finished analysis looks like?
View a sample analysis
Want to follow Septerna, Inc.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow Septerna free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more